Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Otonomy Inc    OTIC

Delayed Quote. Delayed  - 10/16 10:00:00 pm
3.6 USD   +2.86%
09/15 OTONOMY : Provides Business and Financial Update
09/14 OTONOMY : Announces Financial Updates
09/13 Otonomy Provides Business and Financial Update
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/10/2017 10/11/2017 10/12/2017 10/13/2017 10/16/2017 Date
3.425(c) 3.45(c) 3.5(c) 3.5(c) 3.6(c) Last
231 037 238 828 659 097 563 560 949 450 Volume
0.00% +0.73% +1.45% 0.00% +2.86% Change
More quotes
Financials ($)
Sales 2017 1,98 M
EBIT 2017 -98,6 M
Net income 2017 -97,9 M
Finance 2017 4,70 M
Yield 2017 -
Sales 2018 9,48 M
EBIT 2018 -72,9 M
Net income 2018 -72,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 52,9x
Capi. / Sales2018 11,5x
Capitalization 109 M
More Financials
Company
Otonomy, Inc. engages in the research, development, and manufacture of biopharmaceutical products.The firm's portfolio includes therapeutics for diseases and disorders of the ear such as otitis media, acute otitis externa, balance disorders, Ménière's disease, tinnitus, cisplatin-induced hearing... 
More about the company
Surperformance© ratings of Otonomy Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on OTONOMY INC
09/15 OTONOMY : Provides Business and Financial Update
09/14 OTONOMY : Announces Financial Updates
09/13 Otonomy Provides Business and Financial Update
09/05 OTONOMY INC : OTONOMY Faruqi & Faruqi, LLP Encourages Investors Who Suffered Los..
09/02 OTONOMY : Suspends Development of Drug to Treat Ménière’s Disease
09/01 OTONOMY : Reports Results for AVERTS 1 Phase 3 Trial for OTIVIDEX in Patients wi..
08/31 OTONOMY : staggered by an ugly PhIII failure for lead pipeline drug
08/31 BIOTECH MOVERS : Novartis AG (ADR) (NYSE:NVS), Otonomy, Inc. (NASDAQ:OTIC)
08/30 OTONOMY Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceedi..
08/30 Levi & Korsinsky, LLP Notifies Investors of Commencement of an Investigation ..
More news
Sector news : Bio Therapeutic Drugs
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
09/29 Merck to stop development of hepatitis C treatments
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/13Nice setup developing here for $OTIC -  
10/05$OTIC - Short Interest in Otonomy, Inc. #OTIC Decreases By 40.6%  
10/03TPG Group Holdings SBS Advisors Inc. Has $40,703,000 Holdings in Otonomy, Inc.. 
10/02TREND REVERSAL UP ALERT: $OTIC OTONOMY INC ? Trade Ideas via  
09/29Trying again: Best performers in Q3: $DMTX $MRNS $MYOK Worst: $OTIC $AXON $..
5
More tweets
Qtime:77
News from SeekingAlpha
09/20 After Hours Gainers / Losers
09/20 OTONOMY : A Protected And Optimistic Post-Crash Entry Point
09/13 Otonomy restructures after Otividex flop; 1/3 of non-commercial workforce cut..
09/05 Otonomy Fails Phase III - Best To Avoid
09/05 How To Value Biotech Firms?
Chart OTONOMY INC
Duration : Period :
Otonomy Inc Technical Analysis Chart | OTIC | US68906L1052 | 4-Traders
Technical analysis trends OTONOMY INC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 10,7 $
Spread / Average Target 196%
EPS Revisions
Managers
NameTitle
David A. Weber President, Chief Executive Officer & Director
Jay B. Lichter Chairman
Paul E. Cayer CFO, Chief Business & Principal Accounting Officer
Robert Michael Savel Chief Technical Officer
Dean Hakanson Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
OTONOMY INC-77.99%109
GILEAD SCIENCES13.35%106 002
REGENERON PHARMACEUTICALS20.67%47 464
VERTEX PHARMACEUTICALS107.56%38 551
ACTELION23.24%29 919
GENMAB22.08%13 910